Eisai Europe Limited

HATFIELD, England, November 17, 2011 - Eisai Considers Grounds to Appeal the NICE Decision The National Institute for Health and Clinical Excellence (NICE) today published its final appraisal determination (FAD) on Halaven (eribulin).

HATFIELD, England, October 10, 2011 - - Scottish women with metastatic breast cancer denied access to life-prolonging treatment The Scottish Medicines Consortium (SMC) announced today that it does not recommend funding for Halaven▼ (eribulin), a new treatment for locally advanced or metastatic breast cancer.[1] This decision denies seriously ill patients with very limited treatment options access to a drug that has demonstrated a significant improvement in overall survival.[2] Eribulin is a novel monotherapy treatment indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.

HATFIELD, England, August 29, 2011 - 25 abstracts accepted for presentation Eisai and BIAL announced today that 25 abstracts, highlighting an extensive development programme for Zebinix (eslicarbazepine acetate), have been accepted for presentation during the 29th International Epilepsy Congress, taking place in Rome from 28 August until 1 September, 2011.

HATFIELD, England, July 28, 2011 - Eisai today announced that the European Medicines Agency (EMA) has accepted for review their application to extend the use of Zonegran (zonisamide) as monotherapy for newly diagnosed epilepsy patients with partial seizures, with and without second generalisation.

HATFIELD, England, July 20, 2011 - The National Institute for Health and Clinical Excellence (NICE) today issued draft guidance on Halaven (eribulin) for public consultation.